|
Real-time Estimate
Cboe BZX
13:12:20 2026-09-08 EDT
|
5-day change | 1st Jan Change | ||
| 96.18 USD | -0.57% |
|
-1.43% | +21.22% |
| 09-03 | Cvs Health Announces Updated 2026-2027 Covid-19 Vaccines Available At Cvs Pharmacy and Minuteclinic Locations | CI |
| 09-03 | CVS Health Reports Availability of Updated COVID-19 Vaccines | MT |
| Market Cap | 124B 106B 100B 91.33B 170B 11,730B 171B 1,186B 459B 5,995B 465B 454B 19,079B | P/E 2026 * |
14.2x | P/E 2027 * | 13.4x |
|---|---|---|---|---|---|
| Enterprise Value | 176B 151B 142B 130B 242B 16,651B 243B 1,683B 651B 8,511B 660B 645B 27,083B | EV / Sales 2026 * |
0.42x | EV / Sales 2027 * | 0.4x |
| Free-Float |
71.17% | Yield 2026 * |
2.75% | Yield 2027 * | 2.83% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| CVS | Delayed | |
CBOE
| CVS | Real-time | |
|
Tradegate
| CVS | Real-time | |
|
Boerse Muenchen
| CVS | Real-time | |
|
London S.E.
| 0HRS | Delayed | |
|
Mexican S.E.
| CVS * | End-of-day quote | |
|
Xetra
| CVS | Delayed | |
|
Borsa Italiana
| 1CVS | End-of-day quote | |
|
Deutsche Boerse AG
| CVS | Delayed | |
|
Swiss Exchange
| CVS | Delayed | |
|
CBOE
| Real-time | ||
|
CBOE
| 0HRS | Real-time | |
|
Santiago S.E.
| CVS | End-of-day quote | |
|
Santiago S.E.
| CVSCL | End-of-day quote | |
|
Lima
| CVSUS | End-of-day quote | |
|
Wiener Boerse
| CVS | End-of-day quote | |
|
Börse Stuttgart
| CVS | Delayed | |
|
Swiss Exchange
| CVS | Delayed |
Last Transcript : CVS Health Corporation
| 1 day | -0.58% | ||
| 1 week | -1.43% | ||
| Current month | +2.44% | ||
| 1 month | +0.55% | ||
| 3 months | -0.91% | ||
| 6 months | +22.92% | ||
| Current year | +21.22% |
| 1 week | 95.24 |  | 98.5 |
| 1 month | 92.35 | | 98.5 |
| Current year | 69.51 | | 110.68 |
| 1 year | 69.51 | | 110.68 |
| 3 years | 43.56 | | 110.68 |
| 5 years | 43.56 | | 111.25 |
| 10 years | 43.56 | | 111.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 62 | 2024-10-16 |
Ali Keshavarz
PSD | President | - | - |
Brian Newman
DFI | Director of Finance/CFO | 57 | 2025-05-11 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 74 | 2007-02-28 |
Anne Finucane
BRD | Director/Board Member | 73 | 2011-01-19 |
| Director/Board Member | 71 | 2015-03-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/31/26 | Tax | Chief Financial Officer | -2,478 | 0.0002% | ||
| 5/31/26 | Tax | Chief Technology Officer | -7,618 | 0.0006% | ||
| 5/21/26 | Glenview Capital Management LLC
| Sell | Company | -748,462 | 0.0584% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.57% | -1.43% | +36.92% | +46.11% | 124B | |
| -0.89% | -2.92% | -3.97% | +46.75% | 87.68B | |
| +3.07% | -4.31% | -7.53% | +52.45% | 28.36B | |
| -0.18% | +0.31% | +29.82% | +86.55% | 26.17B | |
| +0.26% | -0.34% | -5.27% | -4.72% | 21.58B | |
| -1.91% | -2.43% | +34.77% | +247.10% | 21.34B | |
| +1.10% | +5.38% | -3.61% | +33.10% | 15.79B | |
| -1.25% | -1.90% | -8.34% | -3.02% | 12.11B | |
| -0.96% | +3.60% | +35.66% | +90.98% | 11.73B | |
| -0.07% | -2.85% | -15.40% | +64.27% | 10.2B | |
| Average | -0.12% | -0.26% | +9.30% | +65.96% | 35.87B | |
| Weighted average by Cap. | -0.30% | +0.28% | +15.39% | +58.37% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 418B 359B 338B 308B 575B 39,589B 578B 4,002B 1,548B 20,235B 1,568B 1,534B 64,392B | 429B 369B 347B 317B 591B 40,698B 594B 4,114B 1,592B 20,802B 1,612B 1,577B 66,195B |
| Net income | 8.87B 7.62B 7.17B 6.55B 12.21B 841B 12.28B 84.98B 32.88B 430B 33.3B 32.57B 1,367B | 9.16B 7.87B 7.41B 6.76B 12.61B 868B 12.68B 87.76B 33.95B 444B 34.39B 33.64B 1,412B |
| Net Debt | 51.91B 44.63B 41.99B 38.32B 71.51B 4,921B 71.88B 497B 192B 2,515B 195B 191B 8,004B | 48.85B 42.01B 39.52B 36.06B 67.3B 4,632B 67.65B 468B 181B 2,367B 183B 179B 7,533B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-08 | US$96.13 | -0.63% | 1,333,158 |
| 26-09-04 | US$96.74 | -0.47% | 4,499,060 |
| 26-09-03 | US$97.20 | -0.03% | 4,783,706 |
| 26-09-02 | US$97.23 | -0.38% | 5,403,775 |
| 26-09-01 | US$97.60 | +3.93% | 8,614,487 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CVS Stock
Select your edition
All financial news and data tailored to specific country editions
